Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With Locally Advanced or Metastatic HER2 IHC2+/3+ Esophageal Squamous Cell Carcinoma

NCT06055153 is registered in ClinicalTrials.gov with Changhai Hospital as lead sponsor.

NCT NCT06055153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06055153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With Locally Advanced or Metastatic HER2 IHC2+/3+ Esophageal Squamous Cell Carcinoma
Lead sponsor
Changhai Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
September 30, 2023
Completion date
April 30, 2025
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal squamous carcinoma, her-2 protein overexpression